Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65(13–14):1784–1802. doi:10.1016/j.addr.2013.07.012
   PubMed Web of Science ®Google Scholar
• Yang Z, Shi J, Xie J, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng. 2020;4(1):69–83. doi:10.1038/s41551-019-0485-1
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670–1690. doi:10.3390/cancers6031670
   PubMed Web of Science ®Google Scholar
• Wu J, Chen J, Feng Y, Tian H, Chen X. Tumor microenvironment as the “regulator” and “target” for gene therapy. J Gene Med. 2019;21(7):e3088. doi:10.1002/jgm.3088
   PubMedGoogle Scholar
• Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res. 2012;10(11):1403–1418. doi:10.1158/1541-7786.Mcr-12-0307
   PubMed Web of Science ®Google Scholar
• Ivey JW, Bonakdar M, Kanitkar A, Davalos RV, Verbridge SS. Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Lett. 2016;380(1):330–339. doi:10.1016/j.canlet.2015.12.019
   PubMedGoogle Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–823. doi:10.1038/nnano.2011.166
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y
   PubMed Web of Science ®Google Scholar
• Li L, Wang J, Kong H, Zeng Y, Liu G. Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment. Sci Technol Adv Mater. 2018;19(1):771–790. doi:10.1080/14686996.2018.1528850
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–664. doi:10.1038/nrclinonc.2010.139
   PubMed Web of Science ®Google Scholar
• El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, Torchilin VP. Stimuli-responsive nano-architecture drug-delivery systems to solid tumor micromilieu: past, present, and future perspectives. ACS Nano. 2018;12(11):10636–10664. doi:10.1021/acsnano.8b06104
   PubMed Web of Science ®Google Scholar
• Li F, Yang H, Bie N, et al. Zwitterionic temperature/redox-sensitive nanogels for near-infrared light-triggered synergistic thermo-chemotherapy. ACS Appl Mater Interfaces. 2017;9(28):23564–23573. doi:10.1021/acsami.7b08047
   PubMedGoogle Scholar
• Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016;6:9. doi:10.1186/s13569-016-0049-z
   PubMedGoogle Scholar
• Jhaveri A, Deshpande P, Torchilin V. Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release. 2014;190:352–370. doi:10.1016/j.jconrel.2014.05.002
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776
   PubMed Web of Science ®Google Scholar
• Chen B, Dai W, He B, et al. Current multistage drug delivery systems based on the tumor microenvironment. Theranostics. 2017;7(3):538–558. doi:10.7150/thno.16684
   PubMed Web of Science ®Google Scholar
• Raza A, Rasheed T, Nabeel F, Hayat U, Bilal M, Iqbal HMN. Endogenous and exogenous stimuli-responsive drug delivery systems for programmed site-specific release. Molecules (Basel, Switzerland). 2019;24(6):1117. doi:10.3390/molecules24061117
   PubMed Web of Science ®Google Scholar
• Wang M, Liang Y, Zhang Z, et al. Ag@Fe(3)O(4)@C nanoparticles for multi-modal imaging-guided chemo-photothermal synergistic targeting for cancer therapy. Anal Chim Acta. 2019;1086:122–132. doi:10.1016/j.aca.2019.08.035
   PubMedGoogle Scholar
• Reguera J, Jiménez de Aberasturi D, Henriksen-Lacey M, et al. Janus plasmonic-magnetic gold-iron oxide nanoparticles as contrast agents for multimodal imaging. Nanoscale. 2017;9(27):9467–9480. doi:10.1039/c7nr01406f
   PubMed Web of Science ®Google Scholar
• Zhou S, Ding C, Wang C, Fu J. UV-light cross-linked and pH de-cross-linked coumarin-decorated cationic copolymer grafted mesoporous silica nanoparticles for drug and gene co-delivery in vitro. Mater Sci Eng C Mater Biol Appl. 2020;108:110469. doi:10.1016/j.msec.2019.110469
   PubMedGoogle Scholar
• Lei Q, Wang SB, Hu JJ, et al. Stimuli-responsive “Cluster bomb” for programmed tumor therapy. ACS Nano. 2017;11(7):7201–7214. doi:10.1021/acsnano.7b03088
   PubMed Web of Science ®Google Scholar
• Cheng L, Liu J, Gu X, et al. PEGylated WS(2) nanosheets as a multifunctional theranostic agent for in vivo dual-modal CT/photoacoustic imaging guided photothermal therapy. Adv Mater. 2014;26(12):1886–1893. doi:10.1002/adma.201304497
   PubMed Web of Science ®Google Scholar
• Sun X, Dong S, Li X, et al. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy. Nanomedicine. 2019;20:102017. doi:10.1016/j.nano.2019.102017
   PubMed Web of Science ®Google Scholar
• Kakwere H, Materia ME, Curcio A, et al. Dually responsive gold-iron oxide heterodimers: merging stimuli-responsive surface properties with intrinsic inorganic material features. Nanoscale. 2018;10(8):3930–3944. doi:10.1039/c7nr06726g
   PubMedGoogle Scholar
• Guardia P, Nitti S, Materia ME, et al. Gold-iron oxide dimers for magnetic hyperthermia: the key role of chloride ions in the synthesis to boost the heating efficiency. J Mater Chem B. 2017;5(24):4587–4594. doi:10.1039/c7tb00968b
   PubMedGoogle Scholar
• Truong NP, Gu W, Prasadam I, et al. An influenza virus-inspired polymer system for the timed release of siRNA. Nat Commun. 2013;4:1902. doi:10.1038/ncomms2905
   PubMed Web of Science ®Google Scholar
• Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740–2779. doi:10.1039/c1cs15237h
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14(1):68–77. doi:10.1038/sj.gt.3302843
   PubMed Web of Science ®Google Scholar
• Zhou M, Huang H, Wang D, et al. Light-triggered PEGylation/dePEGylation of the nanocarriers for enhanced tumor penetration. Nano Lett. 2019;19(6):3671–3675. doi:10.1021/acs.nanolett.9b00737
   PubMedGoogle Scholar
• Lee Y, Lee S, Lee DY, Yu B, Miao W, Jon S. Multistimuli-responsive bilirubin nanoparticles for anticancer therapy. Angew Chem Int Ed Engl. 2016;55(36):10676–10680. doi:10.1002/anie.201604858
   PubMed Web of Science ®Google Scholar
• Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;358(9):920–928. doi:10.1056/NEJMct0708376
   PubMed Web of Science ®Google Scholar
• Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci U S A. 2009;106(13):5171–5176. doi:10.1073/pnas.0813132106
   PubMed Web of Science ®Google Scholar
• Zhou X, Chen L, Nie W, et al. Dual-responsive mesoporous silica nanoparticles mediated codelivery of doxorubicin and Bcl-2 SiRNA for targeted treatment of breast cancer. J Phys Chem C. 2016;120(39):22375–22387. doi:10.1021/acs.jpcc.6b06759
   Google Scholar
• Feng W, Nie W, He C, et al. Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers. ACS Appl Mater Interfaces. 2014;6(11):8447–8460. doi:10.1021/am501337s
   PubMed Web of Science ®Google Scholar
• Ma X, Zhao Y, Ng KW, Zhao Y. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chemistry. 2013;19(46):15593–15603. doi:10.1002/chem.201302736
   PubMedGoogle Scholar
• Huschka R, Zuloaga J, Knight MW, Brown LV, Nordlander P, Halas NJ. Light-induced release of DNA from gold nanoparticles: nanoshells and nanorods. J Am Chem Soc. 2011;133(31):12247–12255. doi:10.1021/ja204578e
   PubMed Web of Science ®Google Scholar
• Wang F, Shen Y, Zhang W, et al. Efficient, dual-stimuli responsive cytosolic gene delivery using a RGD modified disulfide-linked polyethylenimine functionalized gold nanorod. J Control Release. 2014;196:37–51. doi:10.1016/j.jconrel.2014.09.026
   PubMed Web of Science ®Google Scholar
• Wang F, Huang Q, Wang Y, Shi L, Shen Y, Guo S. NIR-light and GSH activated cytosolic p65-shRNA delivery for precise treatment of metastatic cancer. J Control Release. 2018;288:126–135. doi:10.1016/j.jconrel.2018.09.002
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354. doi:10.1038/nature12626
   PubMed Web of Science ®Google Scholar
• Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release. 2015;219:192–204. doi:10.1016/j.jconrel.2015.08.017
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang T, Hou C, et al. Mitochondria-specific anticancer drug delivery based on reduction-activated polyprodrug for enhancing the therapeutic effect of breast cancer chemotherapy. ACS Appl Mater Interfaces. 2019;11(32):29330–29340. doi:10.1021/acsami.9b10211
   PubMedGoogle Scholar
• Ruan S, Cao X, Cun X, et al. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials. 2015;60:100–110. doi:10.1016/j.biomaterials.2015.05.006
   PubMed Web of Science ®Google Scholar
• Yu B, Song N, Hu H, Chen G, Shen Y, Cong H. A degradable triple temperature-, pH-, and redox-responsive drug system for cancer chemotherapy. J Biomed Mater Res A. 2018;106(12):3203–3210. doi:10.1002/jbm.a.36515
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu Z, Zhu G. A Platinum(IV) anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance. Angew Chem Int Ed Engl. 2016;55(50):15564–15568. doi:10.1002/anie.201608936
   PubMedGoogle Scholar
• Mo R, Sun Q, Xue J, et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv Mater. 2012;24(27):3659–3665. doi:10.1002/adma.201201498
   PubMed Web of Science ®Google Scholar
• Callahan J, Kopečkov P, Kopeček J. Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers. Biomacromolecules. 2009;10(7):1704–1714. doi:10.1021/bm801514x
   PubMedGoogle Scholar
• Pan L, He Q, Liu J, et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc. 2012;134(13):5722–5725. doi:10.1021/ja211035w
   PubMed Web of Science ®Google Scholar
• Xie J, Bi Y, Zhang H, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020;11:697. doi:10.3389/fphar.2020.00697
   PubMed Web of Science ®Google Scholar
• Lian L, Sun W, Zhong J, et al. Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs. Adv Funct Mater. 2015;25(26):4101–4113. doi:10.1002/adfm.201501248
   Google Scholar
• Beheshti F, Hassanian SM, Khazaei M, et al. Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer. J Cell Physiol. 2018;233(4):2752–2758. doi:10.1002/jcp.26091
   PubMedGoogle Scholar
• Liu J, Guo X, Luo Z, Zhang J, Li M, Cai K. Hierarchically stimuli-responsive nanovectors for improved tumor penetration and programed tumor therapy. Nanoscale. 2018;10(28):13737–13750. doi:10.1039/c8nr02971g
   PubMedGoogle Scholar
• Liu M, Shen S, Wen D, et al. Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment. Nano Lett. 2018;18(4):2294–2303. doi:10.1021/acs.nanolett.7b04976
   PubMedGoogle Scholar
• Zhao M, Liu Y, Hsieh RS, et al. Clickable protein nanocapsules for targeted delivery of recombinant p53 protein. J Am Chem Soc. 2014;136(43):15319–15325. doi:10.1021/ja508083g
   PubMed Web of Science ®Google Scholar
• Li HJ, Du JZ, Du XJ, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci U S A. 2016;113(15):4164–4169. doi:10.1073/pnas.1522080113
   PubMed Web of Science ®Google Scholar
• Wang M, Alberti K, Sun S, Arellano CL, Xu Q. Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy. Angew Chem Int Ed Engl. 2014;53(11):2893–2898. doi:10.1002/anie.201311245
   PubMed Web of Science ®Google Scholar
• Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget. 2015;6(7):4569–4584. doi:10.18632/oncotarget.3174
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle (Georgetown, Tex). 2017;16(8):737–745. doi:10.1080/15384101.2016.1241929
   PubMed Web of Science ®Google Scholar
• Li Y, Li W, Bao W, et al. Bioinspired peptosomes with programmed stimuli-responses for sequential drug release and high-performance anticancer therapy. Nanoscale. 2017;9(27):9317–9324. doi:10.1039/c7nr00598a
   PubMed Web of Science ®Google Scholar
• Arpel A, Sawma P, Spenlé C, et al. Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis. Cell Rep. 2014;8(6):1714–1721. doi:10.1016/j.celrep.2014.07.044
   PubMedGoogle Scholar
• Lächelt U, Wagner E. Nucleic acid therapeutics using polyplexes: a journey of 50 years (and Beyond). Chem Rev. 2015;115(19):11043–11078. doi:10.1021/cr5006793
   PubMed Web of Science ®Google Scholar
• Hao F, Dong S, Yang C, et al. Targeted and efficient delivery of siRNA using tunable polymeric hybrid micelles for tumor therapy. Anticancer Res. 2019;39(3):1169–1178. doi:10.21873/anticanres.13226
   PubMedGoogle Scholar
• Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv. 2013;10(2):215–228. doi:10.1517/17425247.2013.744964
   PubMed Web of Science ®Google Scholar
• Xu F, Zhong H, Chang Y, et al. Targeting death receptors for drug-resistant cancer therapy: codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites. Biomaterials. 2018;158:56–73. doi:10.1016/j.biomaterials.2017.12.018
   PubMedGoogle Scholar
• Tan J, Wang H, Xu F, et al. Poly-γ-glutamic acid-based GGT-targeting and surface camouflage strategy for improving cervical cancer gene therapy. J Mater Chem B. 2017;5(6):1315–1327. doi:10.1039/c6tb02990f
   PubMedGoogle Scholar
• Choi KY, Silvestre OF, Huang X, et al. A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc. 2014;9(8):1900–1915. doi:10.1038/nprot.2014.128
   PubMed Web of Science ®Google Scholar
• Saw PE, Yao H, Lin C, Tao W, Farokhzad OC, Xu X. Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy. Nano Lett. 2019;19(9):5967–5974. doi:10.1021/acs.nanolett.9b01660
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang W, Guo S, et al. PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat Commun. 2016;7:11822. doi:10.1038/ncomms11822
   PubMed Web of Science ®Google Scholar
• Augustine R, Kalva N, Kim HA, Zhang Y, Kim I. pH-responsive polypeptide-based smart nano-carriers for theranostic applications. Molecules (Basel, Switzerland). 2019;24(16):2961. doi:10.3390/molecules24162961
   PubMedGoogle Scholar
• Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. The possible “proton sponge “ effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther. 2013;21(1):149–157. doi:10.1038/mt.2012.185
   PubMed Web of Science ®Google Scholar
• Oh JK. Disassembly and tumor-targeting drug delivery of reduction-responsive degradable block copolymer nanoassemblies. Polym Chem. 2019;10(13):1554–1568. doi:10.1039/c8py01808a
   Google Scholar
• Karimi M, Ghasemi A, Sahandi Zangabad P, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457–1501. doi:10.1039/c5cs00798d
   PubMed Web of Science ®Google Scholar
• Ataullakhanov FI, Vitvitsky VM. What determines the intracellular ATP concentration. Biosci Rep. 2002;22(5–6):501–511. doi:10.1023/a:1022069718709
   PubMedGoogle Scholar
• Wu Y, Zhang X, Li H, et al. A core/shell stabilized polysaccharide-based nanoparticle with intracellular environment-sensitive drug delivery for breast cancer therapy. J Mater Chem B. 2018;6(41):6646–6659. doi:10.1039/c8tb00633d
   PubMedGoogle Scholar
• Liu KS, Liu H, Qi JH, et al. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett. 2012;318(2):180–188. doi:10.1016/j.canlet.2011.12.015
   PubMedGoogle Scholar
• Lu HH, Huang CH, Shiue TY, et al. Highly efficient gene release in spatiotemporal precision approached by light and pH dual responsive copolymers. Chem Sci. 2019;10(1):284–292. doi:10.1039/c8sc01494a
   PubMedGoogle Scholar
• He H, Zhu R, Sun W, Cai K, Chen Y, Yin L. Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery. Nanoscale. 2018;10(6):2856–2865. doi:10.1039/c7nr07677k
   PubMed Web of Science ®Google Scholar
• Tiwari AP, Hwang TI, Oh JM, et al. pH/NIR-responsive polypyrrole-functionalized fibrous localized drug-delivery platform for synergistic cancer therapy. ACS Appl Mater Interfaces. 2018;10(24):20256–20270. doi:10.1021/acsami.7b17664
   PubMedGoogle Scholar
• Zeng X, Wang Y, Han J, et al. Fighting against drug-resistant tumors using a dual-responsive Pt(IV)/Ru(II) bimetallic polymer. Adv Mater. 2020:e2004766. doi:10.1002/adma.202004766.
   PubMedGoogle Scholar
• Zhou J, Han Y, Yang Y, et al. Phospholipid-decorated glycogen nanoparticles for stimuli-responsive drug release and synergetic chemophotothermal therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12(20):23311–23322. doi:10.1021/acsami.0c02785
   PubMedGoogle Scholar
• Chen W, Achazi K, Schade B, Haag R. Charge-conversional and reduction-sensitive poly(vinyl alcohol) nanogels for enhanced cell uptake and efficient intracellular doxorubicin release. J Control Release. 2015;205:15–24. doi:10.1016/j.jconrel.2014.11.012
   PubMed Web of Science ®Google Scholar
• Guo Z, Sui J, Ma M, et al. pH-Responsive charge switchable PEGylated ε-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment. J Control Release. 2020;326:350–364. doi:10.1016/j.jconrel.2020.07.030
   PubMed Web of Science ®Google Scholar
• Yoo J, Sanoj Rejinold N, Lee D, Jon S, Kim YC. Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy. J Control Release. 2017;264:89–101. doi:10.1016/j.jconrel.2017.08.026
   PubMedGoogle Scholar
• Li Y, Xu X, Zhang X, Li Y, Zhang Z, Gu Z. Tumor-specific multiple stimuli-activated dendrimeric nanoassemblies with metabolic blockade surmount chemotherapy resistance. ACS Nano. 2017;11(1):416–429. doi:10.1021/acsnano.6b06161
   PubMed Web of Science ®Google Scholar
• Han H, Valdepérez D, Jin Q, et al. Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy. ACS Nano. 2017;11(2):1281–1291. doi:10.1021/acsnano.6b05541
   PubMed Web of Science ®Google Scholar
• Gao Y, Jia L, Wang Q, et al. pH/Redox dual-responsive polyplex with effective endosomal escape for codelivery of siRNA and doxorubicin against drug-resistant cancer cells. ACS Appl Mater Interfaces. 2019;11(18):16296–16310. doi:10.1021/acsami.9b02016
   PubMed Web of Science ®Google Scholar
• Hyun LJ, Woo CH, Joon MS, Geun CB. Dual-stimuli responsive mesoporous copper (II) sulfide nanocomposite for chemo-photothermal synergistic therapy. Micropor Mesopor Mater. 2020;302. doi:10.1016/j.micromeso.2020.110228.
   Google Scholar
• Yin W, Ke W, Lu N, et al. Glutathione and reactive oxygen species dual-responsive block copolymer prodrugs for boosting tumor site-specific drug release and enhanced antitumor efficacy. Biomacromolecules. 2020;21(2):921–929. doi:10.1021/acs.biomac.9b01578
   PubMed Web of Science ®Google Scholar
• Mondal B, Pandey B, Parekh N, et al. Amphiphilic mannose-6-phosphate glycopolypeptide-based bioactive and responsive self-assembled nanostructures for controlled and targeted lysosomal cargo delivery. Biomater Sci. 2020;8(22):6322–6336. doi:10.1039/d0bm01469a
   PubMedGoogle Scholar
• Han X, Wang L, Du J, Dou J, Yuan J, Shen J. Keratin-dopamine conjugate nanoparticles as pH/GSH dual responsive drug carriers. J Biomater Sci Polym Ed. 2020;1–13. doi:10.1080/09205063.2020.1803182
   Google Scholar
• Song Y, Cai L, Tian Z, Wu Y, Chen J. Phytochemical curcumin-coformulated, silver-decorated melanin-like polydopamine/mesoporous silica composites with improved antibacterial and chemotherapeutic effects against drug-resistant cancer cells. ACS Omega. 2020;5(25):15083–15094. doi:10.1021/acsomega.0c00912
   PubMed Web of Science ®Google Scholar
• Li Y, Hou H, Zhang P, Zhang Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv. 2020;27(1):1044–1053. doi:10.1080/10717544.2020.1785049
   PubMed Web of Science ®Google Scholar
• Su M, Xiao S, Shu M, et al. Enzymatic multifunctional biodegradable polymers for pH- and ROS-responsive anticancer drug delivery. Colloids Surf B Biointerfaces. 2020;193:111067. doi:10.1016/j.colsurfb.2020.111067
   PubMedGoogle Scholar
• Jiang D, Mu W, Pang X, et al. Cascade cytosol delivery of dual-sensitive micelle-tailored vaccine for enhancing cancer immunotherapy. ACS Appl Mater Interfaces. 2018;10(44):37797–37811. doi:10.1021/acsami.8b09946
   PubMed Web of Science ®Google Scholar
• Kim J, Lee YM, Kim H, Park D, Kim J, Kim WJ. Phenylboronic acid-sugar grafted polymer architecture as a dual stimuli-responsive gene carrier for targeted anti-angiogenic tumor therapy. Biomaterials. 2016;75:102–111. doi:10.1016/j.biomaterials.2015.10.022
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shi C, Yang X, et al. pH- and temperature-sensitive hydrogel nanoparticles with dual photoluminescence for bioprobes. ACS Nano. 2016;10(6):5856–5863. doi:10.1021/acsnano.6b00770
   PubMed Web of Science ®Google Scholar
• Lu N, Huang P, Fan W, et al. Tri-stimuli-responsive biodegradable theranostics for mild hyperthermia enhanced chemotherapy. Biomaterials. 2017;126:39–48. doi:10.1016/j.biomaterials.2017.02.025
   PubMed Web of Science ®Google Scholar
• Zhang L, Sheng D, Wang D, et al. Bioinspired multifunctional melanin-based nanoliposome for photoacoustic/magnetic resonance imaging-guided efficient photothermal ablation of cancer. Theranostics. 2018;8(6):1591–1606. doi:10.7150/thno.22430
   PubMed Web of Science ®Google Scholar
• Feng T, Zhou L, Wang Z, et al. Dual-stimuli responsive nanotheranostics for mild hyperthermia enhanced inhibition of Wnt/β-catenin signaling. Biomaterials. 2020;232:119709. doi:10.1016/j.biomaterials.2019.119709
   PubMed Web of Science ®Google Scholar
• Wu S, Butt HJ. Near-infrared-sensitive materials based on upconverting nanoparticles. Adv Mater. 2016;28(6):1208–1226. doi:10.1002/adma.201502843
   PubMed Web of Science ®Google Scholar
• Zhang H, Jiao X, Chen Q, et al. A multi-functional nanoplatform for tumor synergistic phototherapy. Nanotechnology. 2016;27(8):085104. doi:10.1088/0957-4484/27/8/085104
   PubMedGoogle Scholar
• Xu J, Kuang Y, Lv R, et al. Charge convertibility and near infrared photon co-enhanced cisplatin chemotherapy based on upconversion nanoplatform. Biomaterials. 2017;130:42–55. doi:10.1016/j.biomaterials.2017.03.041
   PubMed Web of Science ®Google Scholar
• Yong Y, Zhou L, Zhang S, et al. Gadolinium polytungstate nanoclusters: a new theranostic with ultrasmall size and versatile properties for dual-modal MR/CT imaging and photothermal therapy/radiotherapy of cancer. NPG Asia Mater. 2016;8(5):e273. doi:10.1038/am.2016.63
   Google Scholar
• Yu J, Yin W, Peng T, et al. Biodistribution, excretion, and toxicity of polyethyleneimine modified NaYF(4): yb, Erupconversion nanoparticles in mice via different administration routes. Nanoscale. 2017;9(13):4497–4507. doi:10.1039/c7nr00078b
   PubMedGoogle Scholar
• Dong X, Yin W, Zhang X, et al. Intelligent MoS(2) nanotheranostic for targeted and enzyme-/pH-/NIR-responsive drug delivery to overcome cancer chemotherapy resistance guided by PET imaging. ACS Appl Mater Interfaces. 2018;10(4):4271–4284. doi:10.1021/acsami.7b17506
   PubMed Web of Science ®Google Scholar
• Wang S, Li X, Chen Y, et al. A facile one-pot synthesis of a two-dimensional MoS2/Bi2S3 composite theranostic nanosystem for multi-modality tumor imaging and therapy. Adv Mater. 2015;27(17):2775–2782. doi:10.1002/adma.201500870
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang CX, Chen LG, Yan XP. Dual-stimuli responsive and reversibly activatable theranostic nanoprobe for precision tumor-targeting and fluorescence-guided photothermal therapy. Nat Commun. 2017;8:14998. doi:10.1038/ncomms14998
   PubMed Web of Science ®Google Scholar
• Poulose AC, Veeranarayanan S, Mohamed MS, et al. Multi-stimuli responsive Cu2S nanocrystals as trimodal imaging and synergistic chemo-photothermal therapy agents. Nanoscale. 2015;7(18):8378–8388. doi:10.1039/c4nr07139e
   PubMedGoogle Scholar
• Cao H, Yang Y, Chen X, Shao Z. Intelligent Janus nanoparticles for intracellular real-time monitoring of dual drug release. Nanoscale. 2016;8(12):6754–6760. doi:10.1039/c6nr00987e
   PubMed Web of Science ®Google Scholar
• Lai J, Shah BP, Garfunkel E, Lee KB. Versatile fluorescence resonance energy transfer-based mesoporous silica nanoparticles for real-time monitoring of drug release. ACS Nano. 2013;7(3):2741–2750. doi:10.1021/nn400199t
   PubMed Web of Science ®Google Scholar
• Huang J, Zong C, Shen H, Cao Y, Ren B, Zhang Z. Tracking the intracellular drug release from graphene oxide using surface-enhanced Raman spectroscopy. Nanoscale. 2013;5(21):10591–10598. doi:10.1039/c3nr03264g
   PubMedGoogle Scholar
• Kim H, Kim J, Lee M, Choi HC, Kim WJ. Stimuli-regulated enzymatically degradable smart graphene-oxide-polymer nanocarrier facilitating photothermal gene delivery. Adv Healthcare Mater. 2016;5(15):1918–1930. doi:10.1002/adhm.201600246
   Google Scholar
• Ye S, Wang F, Fan Z, et al. Light/pH-triggered biomimetic red blood cell membranes camouflaged small molecular drug assemblies for imaging-guided combinational chemo-photothermal therapy. ACS Appl Mater Interfaces. 2019;11(17):15262–15275. doi:10.1021/acsami.9b00897
   PubMed Web of Science ®Google Scholar
• Ao L, Wu C, Liu K, et al. Polydopamine-derivated hierarchical nanoplatforms for efficient dual-modal imaging-guided combination in vivo cancer therapy. ACS Appl Mater Interfaces. 2018;10(15):12544–12552. doi:10.1021/acsami.8b02973
   PubMed Web of Science ®Google Scholar
• Hayashi K, Maruhashi T, Nakamura M, Sakamoto W, Yogo T. One-pot synthesis of dual stimulus-responsive degradable hollow hybrid nanoparticles for image-guided trimodal therapy. Adv Funct Mater. 2016;26(47):8613–8622. doi:10.1002/adfm.201603394
   Web of Science ®Google Scholar
• Fang S, Lin J, Li C, et al. Dual-stimuli responsive nanotheranostics for multimodal imaging guided trimodal synergistic therapy. Small. 2017;13(6). doi:10.1002/smll.201602580
   Google Scholar
• Zhou Z, Hu K, Ma R, et al. Dendritic platinum-copper alloy nanoparticles as theranostic agents for multimodal imaging and combined chemophotothermal therapy. Adv Funct Mater. 2016;26(33):5971–5978. doi:10.1002/adfm.201601754
   Google Scholar
• Lin X, Song X, Zhang Y, et al. Multifunctional theranostic nanosystems enabling photothermal-chemo combination therapy of triple-stimuli-responsive drug release with magnetic resonance imaging. Biomater Sci. 2020;8(7):1875–1884. doi:10.1039/c9bm01482a
   PubMedGoogle Scholar
• Sun S, Chen Q, Tang Z, et al. Tumor microenvironment stimuli-responsive fluorescence imaging and synergistic cancer therapy by Carbon-Dot-Cu nanoassemblies. Angew Chem. 2020. doi:10.1002/anie.202007786
   Google Scholar
• Massoumi B, Farnudiyan-Habibi A, Derakhshankhah H, et al. theranosticA novel multi-stimuli-responsive nanomedicine based on FeO@Au nanoparticles against cancer. Drug Dev Ind Pharm. 2020:1–12. doi:10.1080/03639045.2020.1821052.
   Google Scholar
• Gou S, Yang J, Ma Y, et al. Multi-responsive nanococktails with programmable targeting capacity for imaging-guided mitochondrial phototherapy combined with chemotherapy. J Control Release. 2020;327:371–383. doi:10.1016/j.jconrel.2020.08.014
   PubMedGoogle Scholar
• Kuang Y, Zhang Y, Zhao Y, et al. Dual-stimuli-responsive multifunctional GdHfO nanoparticles for MRI-guided combined chemo-/photothermal-/radiotherapy of resistant tumors. ACS Appl Mater Interfaces. 2020;12(32):35928–35939. doi:10.1021/acsami.0c09422
   PubMedGoogle Scholar
• Kang S, Baskaran R, Ozlu B, et al. T-positive Mn-doped multi-stimuli responsive poly(L-DOPA) nanoparticles for photothermal and photodynamic combination cancer therapy. Biomedicines. 2020;8(10):417. doi:10.3390/biomedicines8100417
   PubMedGoogle Scholar
• Wang J, Chang Y, Luo H, et al. Designing immunogenic nanotherapeutics for photothermal-triggered immunotherapy involving reprogramming immunosuppression and activating systemic antitumor responses. Biomaterials. 2020;255. doi:10.1016/j.biomaterials.2020.120153
   Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Sau S, Alsaab HO, Bhise K, Alzhrani R, Nabil G, Iyer AK. Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release. 2018;274:24–34. doi:10.1016/j.jconrel.2018.01.028
   PubMed Web of Science ®Google Scholar
• Selvan SR, Dowling JP, Kelly WK, Lin J. Indoleamine 2,3-dioxygenase (IDO): biology and target in cancer immunotherapies. Curr Cancer Drug Targets. 2016;16(9):755–764. doi:10.2174/1568009615666151030102250
   PubMed Web of Science ®Google Scholar
• Cheng K, Ding Y, Zhao Y, et al. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy. Nano Lett. 2018;18(5):3250–3258. doi:10.1021/acs.nanolett.8b01071
   PubMed Web of Science ®Google Scholar
• Ding Y, Ji T, Zhao Y, et al. Improvement of stability and efficacy of C16Y therapeutic peptide via molecular self-assembly into tumor-responsive nanoformulation. Mol Cancer Ther. 2015;14(10):2390–2400. doi:10.1158/1535-7163.Mct-15-0484
   PubMedGoogle Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Feng B, Zhou F, Hou B, et al. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment. Adv Mater. 2018;30(38). doi:10.1002/adma.201803001
   Google Scholar
• Zheng D-W, Chen J-L, Zhu J-Y, et al. Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy. Nano Lett. 2016;16(7):4341–4347. doi:10.1021/acs.nanolett.6b01432
   PubMed Web of Science ®Google Scholar
• Hou B, Zhou L, Wang H, et al. Engineering stimuli-activatable boolean logic prodrug nanoparticles for combination cancer immunotherapy. Adv Mater. 2020;32(12):e1907210. doi:10.1002/adma.201907210
   PubMedGoogle Scholar
• Huynh E, Leung BY, Helfield BL, et al. In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging. Nat Nanotechnol. 2015;10(4):325–332. doi:10.1038/nnano.2015.25
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–650. doi:10.1016/j.immuni.2011.05.006
   PubMed Web of Science ®Google Scholar
• Yin T, He S, Wang Y. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model. Mol Med Rep. 2015;12(3):3515–3520. doi:10.3892/mmr.2015.3885
   PubMedGoogle Scholar
• Liu Y, Qiao L, Zhang S, et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 2018;66:310–324. doi:10.1016/j.actbio.2017.11.010
   PubMed Web of Science ®Google Scholar
• Hu Q, Chen Q, Gu Z. Advances in transformable drug delivery systems. Biomaterials. 2018;178:546–558. doi:10.1016/j.biomaterials.2018.03.056
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2). Ann Oncol. 2000;11(8):1029–1033. doi:10.1023/a:1008365716693
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951. doi:10.1038/nbt.3330
   PubMed Web of Science ®Google Scholar
• Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response. 2020;18(3):1559325820936161. doi:10.1177/1559325820936161
   Web of Science ®Google Scholar
• Barnes LD, Giuliano EA, Ota J. Cellular localization of Visudyne as a function of time after local injection in an in vivo model of squamous cell carcinoma: an investigation into tumor cell death. Vet Ophthalmol. 2010;13(3):158–165. doi:10.1111/j.1463-5224.2010.00775.x
   PubMedGoogle Scholar
• Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(1):e1416. doi:10.1002/wnan.1416
   Web of Science ®Google Scholar
• Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306–1323. doi:10.7150/thno.14858
   PubMed Web of Science ®Google Scholar
• Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42(12):742–755.
   PubMedGoogle Scholar
• Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release. 2015;219:205–214. doi:10.1016/j.jconrel.2015.08.050
   PubMed Web of Science ®Google Scholar
• Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017;46(12):3830–3852. doi:10.1039/c6cs00592f
   PubMed Web of Science ®Google Scholar